{
    "clinical_study": {
        "@rank": "79122", 
        "acronym": "TPI-287-4RTNI", 
        "arm_group": [
            {
                "arm_group_label": "TPI-287 low dose", 
                "arm_group_type": "Experimental", 
                "description": "2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)"
            }, 
            {
                "arm_group_label": "TPI-287 moderate dose", 
                "arm_group_type": "Experimental", 
                "description": "6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)."
            }, 
            {
                "arm_group_label": "TPI-287 high dose", 
                "arm_group_type": "Experimental", 
                "description": "20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.9% sodium chloride as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and tolerability [maximum tolerated\n      dose (MTD) within planned dosing range] of intravenous (IV) infusions of TPI 287\n      administered once every 3 weeks for 9 weeks (for a total of 4 infusions) in patients with\n      primary four repeat tauopathies (4RT), corticobasal syndrome (CBS) or progressive\n      supranuclear palsy (PSP)."
        }, 
        "brief_title": "Safety Study of TPI-287 to Treat CBS and PSP", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Four Repeat Tauopathies (4RT)", 
            "Corticobasal Syndrome (CBS)", 
            "Progressive Supranuclear Palsy (PSP)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Supranuclear Palsy, Progressive", 
                "Tauopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "The maximum tolerated dose of TPI-287 will be determined through a planned dose escalation\n      over 3 sequential cohorts, each comprising of 11 participants randomized to either TPI-287\n      or placebo. TPI-287 or placebo will be administered as an intravenous infusion once every 3\n      weeks for 9 weeks, for a total of 4 infusions. Participants who successfully complete this\n      phase will have the option of entering into the open label extension phase during which\n      TPI-287 will be administered once every 3 weeks for an additional 6 weeks, for a total of 3\n      extra infusions.\n\n      The doses of TPI 287 will be escalated in sequential cohorts for each diagnosis (i.e.,\n      separate dose escalations will be performed for CBS and PSP).  Subjects will be assigned to\n      cohorts in the order of study entry for each diagnosis.\n\n      Safety and tolerability will be assessed through reporting of adverse events, physical and\n      neurological testing, ECGs, as well as blood and urine analyses. Baseline and end-point\n      measures of cognition and function, MRI brain scans, and cerebrospinal fluid (CSF) biomarker\n      analyses will be used to determine preliminary efficacy of TPI-287 in mild-moderate AD.\n      Pharmacokinetic and pharmacodynamic properties of TPI-287 will be calculated from blood\n      plasma collected after the first infusion, and from CSF collected on the last visit of the\n      placebo-controlled phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Between 50 and 85 years of age (inclusive);\n\n          2. Able to walk 5 steps with minimal assistance (stabilization of one arm or use of\n             cane/walker);\n\n          3. MRI at Screening is consistent with CBS or PSP (\u2264 4 microhemorrhages, and no large\n             strokes or severe white matter disease);\n\n          4. MMSE at Screening is between 14 and 30 (inclusive);\n\n          5. FDA-approved AD medications are sometimes prescribed for CBS and PSP subjects, and\n             are allowed as long as the dose is stable for 2 months prior to Screening. Other\n             medications (except those listed under exclusion criteria) are allowed as long as the\n             dose is stable for 30 days prior to Screening;\n\n          6. FDA-approved Parkinson's medications are allowed as long as the dose is stable for 2\n             months prior to Screening;\n\n          7. Has a reliable study partner who agrees to accompany the subject to visits, and\n             spends at least 5 hours per week with the subject;\n\n          8. Agrees to 2 lumbar punctures;\n\n          9. Signed and dated written informed consent obtained from the subject and the subject's\n             caregiver in accordance with local IRB regulations;\n\n         10. Males and all WCBP agree to abstain from sex or use an adequate method of\n             contraception for the duration of the study and for 30 days after the last dose of\n             study drug.\n\n             Adequate contraceptive methods include those with a low failure rate, i.e., less than\n             1% per year, when used consistently and correctly, such as complete abstinence from\n             sexual intercourse with a potentially fertile partner, and some double barrier\n             methods (condom with spermicide) in conjunction with use by the partner of an\n             intrauterine device (IUD), diaphragm with spermicide, oral contraceptives, birth\n             control patch or vaginal ring, oral, or injectable or implanted contraceptives.\n\n             For this study, a woman who has been surgically sterilized or who has been in a state\n             of amenorrhea for more than two years will be deemed not to be of childbearing\n             potential;\n\n             For PSP Only\n\n         11. Meets National Institute of Neurological Disorders and Stroke - Society for\n             Progressive Supranuclear Palsy (NINDS-SPSP) probable or possible PSP criteria (Litvan\n             et al. 1996a), as modified for the Neuroprotection and Natural History in Parkinson\n             Plus Syndromes (NNIPPS) clinical trial (Bensimon et al. 2009).\n\n        For CBS Only\n\n        11.            Meets 2013 consensus criteria for possible or probable corticobasal\n        degeneration, CBS subtype (Armstrong et al. 2013).\n\n        Exclusion Criteria:\n\n          1. Meets National Institute on Aging-Alzheimer's Association Workgroups criteria for\n             probable AD (McKhann et al. 2011);\n\n          2. Any medical condition other than CBS or PSP that could account for cognitive deficits\n             (e.g., active seizure disorder, stroke, vascular dementia);\n\n          3. A prominent and sustained response to levodopa therapy;\n\n          4. History of significant cardiovascular, hematologic, renal, or hepatic disease (or\n             laboratory evidence thereof);\n\n          5. History of significant peripheral neuropathy;\n\n          6. History of major psychiatric illness or untreated depression;\n\n          7. Neutrophil count <1,500/mm3, platelets <100,000/mm3, serum creatinine >1.5 x upper\n             limit of normal (ULN), total bilirubin >1.5 x ULN, alanine aminotransferase (ALT) >3\n             x ULN, aspartate aminotransferase (AST) >3 x ULN, or INR >1.2 at Screening\n             evaluations;\n\n          8. Evidence of any clinically significant findings on Screening or baseline evaluations\n             which, in the opinion of the Investigator would pose a safety risk or interfere with\n             appropriate interpretation of study data;\n\n          9. Current or recent history (within four weeks prior to Screening) of a clinically\n             significant bacterial, fungal, or mycobacterial infection;\n\n         10. Current clinically significant viral infection;\n\n         11. Major surgery within four weeks prior to Screening;\n\n         12. Unable to tolerate MRI scan at Screening;\n\n         13. Any contraindication to or unable to tolerate lumbar puncture at Screening, including\n             use of  anti-coagulant medications such as warfarin. Daily administration of 81 mg\n             aspirin will be allowed as long as the dose is stable for 30 days prior to Screening;\n\n         14. Subjects who, in the opinion of the Investigator, are unable or unlikely to comply\n             with the dosing schedule or study evaluations;\n\n         15. Previous exposure to microtubule inhibitors (including TPI 287) within 5 years of\n             Screening.  Treatment with microtubule inhibitors other than TPI 287 while on study\n             will not be allowed;\n\n         16. Participation in another interventional clinical trial within 3 months of Screening;\n\n         17. Treatment with another investigational drug within 30 days of Screening. Treatment\n             with investigational drugs other than TPI 287 while on study will not be allowed;\n\n         18. Known hypersensitivity to the inactive ingredients in the study drug;\n\n         19. Pregnant or lactating;\n\n         20. Positive pregnancy test at Screening or Baseline (Day 1);\n\n         21. Cancer within 5 years of Screening, except for basal cell carcinoma;\n\n             For CBS Only:\n\n         22. History or evidence at Screening of cortical amyloid levels on 18F florbetapir PET\n             scans consistent with underlying AD;\n\n         23. History of serum or plasma progranulin level less than one standard deviation below\n             the normal subject mean for the laboratory performing the assay;\n\n         24. History or evidence at Screening of known disease-associated mutations in GRN or\n             C9ORF72 genes to rule out CBS due to TDP-43 pathology;\n\n         25. History of known disease-associated mutations in ribosomal protein L3 [TDP- 43 gene\n             (TARBP)], chromatin modifying protein 2B (CHMPB2) or valosin containing protein (VCP)\n             genes or any other frontotemporal lobar degeneration (FTLD) causative genes\n             discovered during the course of the trial and not associated with underlying tau\n             pathology."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "82 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133846", 
            "org_study_id": "TPI287-4RT-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "TPI-287 low dose", 
                "description": "2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.", 
                "intervention_name": "TPI 287  2 mg/m2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TPI-287 high dose", 
                "description": "20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class", 
                "intervention_name": "TPI-287 20 mg/m2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "TPI-287 low dose", 
                    "TPI-287 moderate dose", 
                    "TPI-287 high dose", 
                    "Placebo"
                ], 
                "description": "500mL 0.9% sodium chloride", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "TPI-287 moderate dose", 
                "description": "6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class", 
                "intervention_name": "TPI-287 6.3 mg/m2", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "4RT, CBS, PSP, CBD, TPI-287", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "adbrain@uab.edu", 
                    "last_name": "Penny Forsyth, LPN", 
                    "phone": "205-996-3679"
                }, 
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "University of Alabama"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94158"
                    }, 
                    "name": "University of California, San Francisco"
                }, 
                "investigator": {
                    "last_name": "Adam Boxer, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy", 
        "other_outcome": [
            {
                "description": "A lumbar puncture will be performed at the screening and final visits to obtain cerebrospinal fluid (CSF).  CSF biomarkers of neurodegeneration (neurofilament light chain), total tau, tau isoforms and fragments, and tau phosphopeptides.", 
                "measure": "CSF biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Screening and 1 Week after completion of the fourth study infusion"
            }, 
            {
                "description": "Brain MRI scans will be performed to explore effects of changes in brain network functional and structural connectivity, as well as perfusion after administration of study drug.", 
                "measure": "Brain MRI scan", 
                "safety_issue": "No", 
                "time_frame": "Screening and 2 Weeks after last double-blind infusion"
            }, 
            {
                "description": "The Progressive Supranuclear Palsy Rating Scale (PSPRS), Schwab and England Activities of Daily Living (SEADL), clinical dementia rating scale sum of boxes (CDR-SB-FTLD) will be conducted.", 
                "measure": "Degree of disability", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1 Week after completion 4th infusion"
            }, 
            {
                "description": "One-minute phonemic verbal fluency (PVC) test for works starting in \"F\", \"A\" and \"S\", Mini-Mental State Examination (MMSE)", 
                "measure": "Cognition", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1 Week after 4th study infusion"
            }, 
            {
                "description": "The Geriatric Depression Scale (GDS) will be conducted to determine effect a", 
                "measure": "Behavior", 
                "safety_issue": "No", 
                "time_frame": "Screening and 2 Weeks after last infusion"
            }
        ], 
        "overall_contact": {
            "email": "echuu@memory.ucsf.edu", 
            "last_name": "Emmeline Chuu, BA", 
            "phone": "4154760671"
        }, 
        "overall_contact_backup": {
            "email": "mkoestler@memory.ucsf.edu", 
            "last_name": "Mary Koestler, RN, PhD", 
            "phone": "4154760661"
        }, 
        "overall_official": {
            "affiliation": "UCSF Memory and Aging Center", 
            "last_name": "Adam Boxer, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the safety and tolerability [maximum tolerated dose (MTD) within planned dosing range] of intravenous (IV) infusions of TPI 287 administered once every 3 weeks for 9 weeks (for a total of 4 infusions) in patients with primary four repeat tauopathies (4RT): corticobasal syndrome (CBS) or progressive supranuclear palsy (PSP).", 
            "measure": "Maximum tolerated dose of TPI-287 in patients with primary 4RT; CBS or PSP.", 
            "safety_issue": "Yes", 
            "time_frame": "21 months (first subject enrolled to last subject completed)"
        }, 
        "reference": [
            {
                "PMID": "23359374", 
                "citation": "Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Tr\u00f6ster AI, Vidailhet M, Weiner WJ. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013 Jan 29;80(5):496-503. doi: 10.1212/WNL.0b013e31827f0fd1."
            }, 
            {
                "PMID": "8710059", 
                "citation": "Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996 Jul;47(1):1-9. Review."
            }, 
            {
                "PMID": "19029129", 
                "citation": "Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN; NNIPPS Study Group. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009 Jan;132(Pt 1):156-71. Epub 2008 Nov 23."
            }, 
            {
                "PMID": "21514250", 
                "citation": "McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21."
            }, 
            {
                "PMID": "24433963", 
                "citation": "Brunden KR, Trojanowski JQ, Smith AB 3rd, Lee VM, Ballatore C. Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. Bioorg Med Chem. 2013 Dec 30. pii: S0968-0896(13)01054-7. doi: 10.1016/j.bmc.2013.12.046. [Epub ahead of print] PubMed"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133846"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Francisco", 
            "investigator_full_name": "Adam Boxer", 
            "investigator_title": "Adam Boxer, M.D., Ph.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To determine the pharmacokinetic (PK) profile of TPI 287 in plasma after a single IV infusion of TPI 287 and the steady-state cerebrospinal (CSF) concentration of TPI 287 1 week after completion of the fourth infusion.", 
            "measure": "TPI-287 levels in blood plasma and cerebrospinal fluid", 
            "safety_issue": "No", 
            "time_frame": "21 months (first subject enrolled to last subject completed)"
        }, 
        "source": "University of California, San Francisco", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "CBD Solutions", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tau Consortium", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of California, San Francisco", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}